- Home
- TDUP vs DNTH Comparison
TDUP vs DNTH Comparison
Compare TDUP & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TDUP
- DNTH
- Stock Information
- Founded
- TDUP 2009
- DNTH 2015
- Country
- TDUP United States
- DNTH United States
- Employees
- TDUP N/A
- DNTH N/A
- Industry
- TDUP Catalog/Specialty Distribution
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- TDUP Consumer Discretionary
- DNTH Health Care
- Exchange
- TDUP Nasdaq
- DNTH Nasdaq
- Market Cap
- TDUP 1.3B
- DNTH 1.4B
- IPO Year
- TDUP 2021
- DNTH N/A
- Fundamental
- Price
- TDUP $7.87
- DNTH $33.22
- Analyst Decision
- TDUP Buy
- DNTH Strong Buy
- Analyst Count
- TDUP 3
- DNTH 11
- Target Price
- TDUP $12.50
- DNTH $65.22
- AVG Volume (30 Days)
- TDUP 1.5M
- DNTH 516.1K
- Earning Date
- TDUP 11-03-2025
- DNTH 11-07-2025
- Dividend Yield
- TDUP N/A
- DNTH N/A
- EPS Growth
- TDUP N/A
- DNTH N/A
- EPS
- TDUP N/A
- DNTH N/A
- Revenue
- TDUP $298,376,000.00
- DNTH $4,854,000.00
- Revenue This Year
- TDUP $18.15
- DNTH N/A
- Revenue Next Year
- TDUP $9.93
- DNTH N/A
- P/E Ratio
- TDUP N/A
- DNTH N/A
- Revenue Growth
- TDUP 34.31
- DNTH 17.87
- 52 Week Low
- TDUP $0.50
- DNTH $13.37
- 52 Week High
- TDUP $12.28
- DNTH $40.16
- Technical
- Relative Strength Index (RSI)
- TDUP 32.84
- DNTH 44.26
- Support Level
- TDUP $8.49
- DNTH $32.28
- Resistance Level
- TDUP $9.45
- DNTH $35.40
- Average True Range (ATR)
- TDUP 0.44
- DNTH 1.72
- MACD
- TDUP -0.06
- DNTH -0.23
- Stochastic Oscillator
- TDUP 6.08
- DNTH 14.73
About TDUP ThredUp Inc.
ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app and RaaS partners. Geographically, the majority of the company's revenue is generated from United States.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.